KRAS and cancer: In contrast to KRAS mutations, those in BRAF have the ability to cause genomic rearrangements in colon cells that can potentially sensitize them to apoptosis a major advantage in cancer therapeutics, since deregulation of apoptosis can lead to growth advantage in cancer cells.